XML 33 R28.htm IDEA: XBRL DOCUMENT v2.4.0.8
Investments in Joint Ventures and Related Party Transactions (Tables)
3 Months Ended
Mar. 31, 2014
Schedule of Equity Method Investments [Line Items]  
Summarized financial information on Solazyme Bunge JV's Balance Sheets and Income Statements
Summarized information on the Solazyme Bunge JV’s balance sheets and income statements as of March 31, 2014 and December 31, 2013 and for the three months ended March 31, 2014 and 2013, respectively, was as follows (in thousands):
 
As of and for the Three Months Ended March 31, 2014
 
As of December 31, 2013 and for the Three Months Ended March 31, 2013
Current assets
$
4,302

 
$
9,872

Noncurrent assets
180,253

 
127,346

Total assets
$
184,555

 
$
137,218

Current liabilities
44,098

 
20,798

Noncurrent liabilities
102,678

 
90,933

JV's partners' capital, net
37,779

 
25,487

Total liabilities and partners' capital, net
$
184,555

 
$
137,218

Net sales
$

 
$

Net losses
$
5,601

 
$
1,435

Summary of Carrying Amounts of Assets and Fair Value of Liabilities Included in Condensed Consolidated Balance Sheet and Maximum Loss Exposure in VIE
The following table summarizes the carrying amounts of the assets and the fair value of the liabilities included in the Company’s condensed consolidated balance sheet and the maximum loss exposure related to the Company’s interest in its unconsolidated VIE (the Solazyme Bunge JV) as of March 31, 2014 (in thousands):
 
Assets
 
Liabilities
 
 
VIE
Accounts
Receivable
 
Unbilled
Revenues
 
Investments in
Unconsolidated
Joint Ventures
 
Loan
Guarantee
 
Maximum
Exposure
to Loss (1)
Solazyme Bunge JV
$
7,256

 
$
1,705

 
$
28,191

 
$

 
$
70,801

 
(1)
Includes maximum exposure to loss attributable to the Company’s bank guarantee required to be provided for the Solazyme Bunge JV of R$35.4 million (approximately $15.6 million based on the exchange rate at March 31, 2014), the Company's corporate guarantee of $5.0 million (See Note 12) and non-cancelable purchase obligations of R$29.5 million (approximately $13.0 million based on the exchange rate at March 31, 2014).